




# B2B-Licensing Product List



GL<sup>®</sup>Pharma



## ORAL SOLIDS

Lannach 

---

## About Us

We are committed to developing and commercializing innovative medicines for the treatment of severe and chronic conditions worldwide.

As a trusted partner in healthcare, we collaborate closely with physicians, pharmacists, patients, and pharmaceutical wholesalers. As an international company, we market our products through a strong network of license partners and subsidiaries in more than 65 countries.

---

## Core Competencies

GL Pharma was formed through the merger of the pharmaceutical companies Gerot and Lannacher and has a history spanning more than 70 years.

We develop, manufacture, and market differentiated branded medicines as well as high-quality off-patent products to support the well-being of patients in Austria and international markets.

Our **core expertise** is concentrated in three key therapeutic areas:

- Cardiovascular system
- Central nervous system
- Opioid substitution & Pain therapy

GL<sup>®</sup>Pharma

---

## Manufacturing Sites

### Lannach/Graz, AT

Solid oral dosage forms are a core strength of our research and development activities at our headquarters in Lannach. We specialize in the development of technically challenging products, leveraging a broad range of innovative formulation technologies.

### Vienna, AT

Our Vienna team focuses on the development of liquid dosage forms, including sterile preparations. We are driven by user-friendly, compliance-supporting solutions that improve patient experience and outcomes.

---

## Our Approach

We continuously invest in pharmaceutical research and development to improve patients' lives every day.

Innovation is the foundation of our organic growth. Our experienced scientific teams have a strong track record and are supported by collaborations with leading partners – helping us stay at the forefront of pharmaceutical development.



**LIQUIDS/INJECTABLES**

Vienna 

---

## Your Partner Of Choice

Markets

50  
Markets

Active in more than 50  
markets worldwide

Team

1.200  
Employees

1.200 employees in  
15 countries

Revenue

350 M€  
500 M€

350 M€ GL Pharma  
500 M€ group revenue  
incl. Genericon Pharma

Production/Volume

4,5 bn





4,5 bn defined single doses

MAs

3.000  
Approved  
MAs

3.000 approved  
marketing authorizations

# You Can Find Us Here

-  Headquarter - Austria
-  Subsidiaries and representative offices
-  Licensing and distribution partners
-  Cooperation with Bausch Health



---

## Therapeutic Areas

**Cardiovascular**

**Depression**

**Diabetes**

**Epilepsy**

**Opioid Use Disorder**







**Pain**

**Vitamins and Minerals**

**Cancer and Rare Disease**






## Cardiovascular

Active Substance	Dosage Form	Form	Strength	Indication	Dossier
Acetylsalicylic Acid	gastro-resistant tablets		75 mg, 100 mg, 160 mg	Anti-thrombotic	available
	tablets		75 mg, 100 mg		
Bempedoic Acid	film-coated tablets		180 mg	Lipid Modification	Q1 2027
Bempedoic Acid + Ezetimibe	film-coated tablets		180 mg + 10 mg	Lipid Modification	Q4 2027
Candesartan + Chlorthalidone	tablets		8 mg + 12.5 mg, 16 mg + 12.5 mg, 32 mg + 12.5 mg, 32 mg + 25 mg	High Blood Pressure	2027
Sacubitril + Valsartan	film-coated tablets		24 mg + 26 mg, 49 mg + 51 mg, 97 mg + 103 mg	High Blood Pressure	Q2 2027







# Depression

Active Substance	Dosage Form	Form	Strength	Dossier	Zone Iva/b
Fluoxetine	film-coated tablets		20 mg, 40 mg	available	<i>Iva/b stability data available (20 mg)</i>
Trazodone	oral solution		10 mg/ml (120 ml)	available	<i>Iva/b stability data available</i>
Vortioxetine	film-coated tablets		5 mg, 10 mg, 15 mg, 20 mg	available	














## Diabetes

Active Substance	Dosage Form	Form	Strength	Dossier
Dapagliflozin	film-coated tablets		5 mg, 10 mg	available
Dapagliflozin + Metformin	film-coated tablets		5 mg + 850 mg, 5 mg + 1000 mg	available
Empagliflozin	film-coated tablets		10 mg, 25 mg	Q1 2026
Empagliflozin + Metformin	film-coated tablets		5 mg + 850 mg, 5 mg + 1000 mg, 12.5 mg + 850 mg, 12.5 mg + 1000 mg	Q4 2026














# Epilepsy

Active Substance	Dosage Form	Form	Strength	Dossier	Zone Iva/b
Brivaracetam	film-coated tablets		10 mg, 25 mg, 50 mg, 75 mg, 100 mg	available	
Eslicarbazepine Acetate	tablets		200 mg, 400 mg, 600 mg, 800 mg	available	
Ethosuximide	syrup		50 mg/ml (250 ml)	available	<i>Iva/b stability data available</i>
Lacosamide	film-coated tablets		50 mg, 100 mg, 150 mg, 200 mg	available	<i>Iva/b stability data available</i>
	oral solution		10 mg/ml (200 ml, 500 ml)	available	
	solution for infusion		ampoules: 10 mg/ml (10 ml, 20 ml)	available	<i>Iva/b stability data available</i>
		vials: 10 mg/ml (20 ml)			
Levetiracetam	oral solution		100 mg/ml (150 ml, 300 ml)	available	
	conc. for oral solution		vials: 100 mg/ml (5 ml)	available	<i>Iva/b stability data available</i>
Perampanel	film-coated tablets		2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg	available	<i>Iva/b stability data available</i>
Valproic Acid	oral solution		300 mg/ml (100 ml)	available	<i>Iva/b stability data available</i>














## Opioid Use Disorder

Active Substance	Dosage Form	Form	Strength	Dossier	Zone Iva/b
Buprenorphine	sublingual tablets		1 mg, 2 mg	available	
			4 mg, 6 mg, 8 mg, 12 mg, 16 mg		
Buprenorphine + Naloxone	sublingual tablets		2 mg + 0.5 mg, 4 mg + 1 mg, 8 mg + 2 mg	available	<i>Iva/b stability data available</i>
			12 mg + 3 mg	available	
Levomethadone	tablets	 /  / 	2,5 mg, 5 mg, 10 mg, 20 mg, 30 mg	available	<i>Iva/b stability data available</i>
	conc. for oral solution		5 mg/ml (100 ml, 150 ml, 300 ml, 500 ml, 1000 ml)	available	
Methadone	tablets	 /  / 	5 mg, 10 mg, 20 mg, 40 mg, 60 mg	available	<i>Iva/b stability data available</i>
	conc. for oral solution		10 mg/ml (100 ml, 150 ml, 300 ml, 500 ml, 1000 ml)	available	











# Pain

Active Substance	Dosage Form	Form	Strength	Dossier	Zone Iva/b
Buprenorphine	sublingual tablets		0.2 mg, 0.4 mg	available	
Esketamine	solution for injection		ampoules: 5 mg/ml (2 ml, 5 ml, 10 ml), 25 mg/ml (2 ml, 5 ml, 10 ml)	available	<i>Iva/b stability data available</i>
			vials: 5 mg/ml (5 ml, 10 ml, 20 ml), 25 mg/ml (5 ml, 10 ml, 20 ml)		
Hydromorphone	film-coated tablets		1.3 mg, 2.6 mg	available	
	prolonged-release capsules		2 mg, 4 mg, 8 mg, 16 mg, 24 mg	2027	
	solution for injection		ampoules: 2 mg/ml (1 ml), 10 mg/ml (1 ml, 10 ml), 20 mg/ml (1 ml), 50 mg/ml (1 ml)	available	<i>Iva/b stability data available</i>
Ketamine	solution for injection or infusion		ampoules: 10 mg/ml (2 ml, 5 ml, 10 ml), 50 mg/ml (2 ml, 5 ml, 10 ml)	available	<i>Iva/b stability data available</i>
			vials: 10 mg/ml (5 ml, 10 ml, 20 ml), 50 mg/ml (5 ml, 10 ml, 20 ml)		
Metamizole	solution for injection		ampoules: 500 mg/ml (2 ml, 5 ml)	available	<i>Iva/b stability data available</i>
Morphine	solution for injection		ampoules: 10 mg/ml (1 ml)	available	<i>Iva/b stability data available</i>
			vials: 10 mg/ml (10 ml), 20 mg/ml (10 ml)		











# Pain

Active Substance	Dosage Form	Form	Strength	Dossier	Zone Iva/b
Oxycodone	film-coated tablets		5 mg, 10 mg, 20 mg	available	<i>Iva/b stability data available</i>
	prolonged-release tablets		5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg	available	
	oral solution		1 mg/ml (100 ml, 250 ml, 300 ml) 10 mg/ml (30 ml, 100 ml, 120 ml)	available	<i>Iva/b stability data available</i>
	solution for injection or infusion		ampoules (or bottles): 10 mg/ml (1 ml, 2 ml)	available	<i>Iva/b stability data available</i>
Oxycodone + Naloxone	prolonged-release tablets		5 mg + 2.5 mg, 10 mg + 5 mg, 20 mg + 10 mg, 30 mg + 15 mg, 40 mg + 20 mg	available	
Tapentadol	film-coated tablets		25 mg, 50 mg, 75 mg, 100 mg	available	<i>Iva/b stability data available</i>
	prolonged-release tablets		25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg		
	oral solution		20 mg/ml (100 ml, 200 ml)		





## Vitamins and Minerals

Active Substance	Dosage Form	Form	Strength	Indication	Dossier
Folic Acid	tablets		1 mg, 5 mg	Folic Acid Deficiency	available
Fe <sup>2+</sup> + Ascorbic Acid + Folic Acid	capsules		66.7 mg + 100 mg + 0.8 mg	Anemia during Pregnancy	available
Potassium Iodide	tablets		65 mg	Radiation Pro-phylaxis	available
Vitamin B <sub>1</sub> (B <sub>1</sub> = Benfotiamine)	film-coated tablets		50 mg, 150 mg, 300 mg	Vitamin B <sub>1</sub> Deficiency	available
Vitamin B <sub>1</sub> +B <sub>6</sub> (B <sub>1</sub> = Benfotiamine)	film-coated tablets		100 mg + 100 mg	Vitamin B Deficiency	available
Vitamin B <sub>1</sub> +B <sub>6</sub> +B <sub>12</sub> (B <sub>1</sub> = Benfotiamine)	film-coated tablets		40 mg + 90 mg + 0.25 mg	Vitamin B Deficiency	available
Vitamin B <sub>12</sub> (Hydroxocobalamin)	solution for injection		ampoules: 1 mg/ml (1 ml)	Vitamin B <sub>12</sub> Deficiency	available
Vitamin B <sub>12</sub> (Cyanocobalamin)	film-coated tablets		1 mg, 2 mg	Vitamin B <sub>12</sub> Deficiency	Q4 2026



---

## Cancer & Rare Disease

Active Substance	Dosage Form	Form	Strength	Indication	Dossier
8-Methoxypsoralen	ampoules		0.02 mg/ml (5 ml)	Cutaneous T-Cell Lymphoma	<i>Zone Iva/b: stability data available</i>
Miglustat	capsules		100 mg	Type 1 Gaucher Disease	available

---

---

## Contact



**Andreas Gasser**

*Head of Licensing & Business Development*

M: +43 664 85 26 211

E: andreas.gasser@gl-pharma.at



**Katharina Weitzer**

*Head of In-Licensing*

M: +43 664 35 76 210

E: katharina.weitzer@gl-pharma.at



**Michael Bartenstein**

*Managing Director*

M: +43 664 23 07 667

E: michael.bartenstein@gl-pharma.com



**G.L. Pharma GmbH**  
Schlossplatz 1  
A-8502 Lannach  
E: [licensing@gl-pharma.at](mailto:licensing@gl-pharma.at)  
T: +43 3136 82 577

